ADARx Pharmaceuticals to Present at the UBS Global Biopharma Conference
ADARx Pharmaceuticals, Inc. ADRX
$13.84
▲ +0.29%
(+$0.04)
Open
$13.65
Prev Close
$13.80
Day Range
$13.39 – $14.31
52W Range
$12.50 – $23.21
Market Cap
$1.53B
Beta
3.71
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| IPO Date | 2026-09-25 |
| Website | adarx.com ↗ |
| Phone | 18772327974 |
| Shares Out. | 106,801,325 |
About ADARx Pharmaceuticals, Inc.
Adarx Pharmaceuticals Inc is a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases. Its pipeline includes three clinical-stage programs and two advanced preclinical programs. The three hepatic-targeted programs are agazisiran, onvuzosiran, and ADX-626, while the two extrahepatic-targeted programs are ADX-077 and ADX-199.
ADARx Pharmaceuticals, Inc. is a publicly traded company under the ticker symbol ADRX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.